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Abstract
Introduction: The presence of circulating Ro/SSA and La/SSB autoantibodies has become an important marker in
the classification criteria for primary Sjögren’s syndrome (pSS). Plasma cells producing these autoantibodies are
mainly high affinity plasma cells originating from germinal centre reactions. When exposed to the right
microenvironment these autoimmune plasma cells become long-lived and resistant to immunosuppressive
treatment. Since autoimmune plasma cells have been detected in the salivary glands of SS patients, we wanted to
investigate if the glandular microenvironment is suitable for plasma cell survival and if glandular residing plasma
cells are the long-lived plasma cell subset.
Methods: Single, double and triple immunohistochemistry as well as immunofluorescence staining was performed
on minor salivary gland tissue retrieved from pSS, chronically inflamed and normal subjects.
Results: We detected significant numbers of CD138+, non-proliferating, Bcl-2 expressing plasma cells in the salivary
glands of pSS patients with high focus score (FS). Furthermore, we demonstrated that CXCL12 and interleukin (IL)-6
survival factors were highly expressed in pSS salivary gland epithelium and by focal mononuclear infiltrating cells.
Notably, adipocytes when present in the salivary gland tissue were an important source of CXCL12. We clearly
demonstrate that plasma cells are localised in close proximity to CXCL12 and IL-6 expressing cells and thus that
the environment of salivary glands with high FS provide factors vital for plasma cell survival.
Conclusions: Plasma cells residing in the salivary glands of pSS patients with high FS showed phenotypic
characteristics of the long-lived plasma cell subtype. Furthermore, the pSS salivary gland microenvironment
provided niches rich in factors vital for plasma cell survival.
Introduction
Sjögren’s syndrome (SS) is a heterogeneous autoimmune
disease characterized by focal mononuclear cell infiltra-
tion in the exocrine glands and high serum titres of Ro/
SSA, La/SSB and rheumatoid factor (RF) autoantibodies.
Plasma cells producing these autoantibodies are primar-
ily class-switched, somatically mutated IgG plasma cells
that origin from germinal centers (GCs) reactions [1].
However, detection of autoreactive plasma cells in the
inflamed salivary glands [2,3] and presence of IgA
autoantibodies in sera and saliva of SS patients [4-6]
raise questions about the origin and contribution of sali-
vary gland plasma cells to the pathogenesis of SS.
In addition to plasma cells, the focal infiltrates in sali-
vary glands of SS patients consist of T-cells, B-cells,
macrophages, follicular dendritic cells, dendritic cells
and plasmacytoid dendritic cells [7-10]. In approxi-
mately one-fourth of patients with primary SS (pSS), the
accumulating cells form structures that resemble GCs as
seen in secondary lymphoid organs [11-15]. Together
with the fact that both Ro and La antigens have been
detected in the salivary glands of SS patients [16,17]
there exists a possibility that autoimmune plasma cells
are produced at the site of inflammation. Another
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prises factors necessary for prolonged plasma cell survi-
val and that autoantibodies are being produced by
plasma cells independently of activation and differentia-
tion of new B-cells. This phenomenon has been shown
for the bone marrow residing plasma cells that in the
presence of particular survival signals produce circulat-
ing immunoglobulins in an antigen independent fashion
[18-24]. The bone marrow subset of plasma cells is
often referred to as a long-lived plasma cell subset.
The importance of long-lived plasma cells in autoim-
munity has been brought to light after observations
made during clinical studies utilizing the B-cell deplet-
ing monoclonal antibody rituximab in systemic lupus
erythematosus. As an outcome, anti-CD20-treated auto-
immune patients showed drastic reductions in B-cell
numbers, but unchanged serum levels of autoantibodies
[25,26]. Thus, it has been proposed that at least some
portion of these autoantibodies is being produced not
by newly generated cells but by pre-existing long-lived
plasma cells, unaffected by treatment.
In order to survive, long-lived plasma cells need con-
tact with particular factors present in their environment.
In the bone marrow these survival signals are provided
by the so-called survival niches generated by bone mar-
row stroma [22,23,27-29]. Interestingly, many of the sur-
vival molecules in particular cytokines and chemokines,
are also important modulators of the immune responses
that occur within the inflamed tissues. In the salivary
glands of SS patients, the mononuclear cell infiltrates
are one of the hallmarks of the disease. However, it is
the glandular microenvironment and stromal cells of the
glands that are responsible for accumulation, location
and retention of the inflammatory cells [30].
In the present study we aimed to investigate: I) If the
microenvironment of the salivary glands of pSS patients
provides factors necessary for plasma cell survival and if
plasma cells are indeed in close contact with these fac-
tors; II) If plasma cells present in minor salivary glands
of patients with pSS are potential candidates for the
long-lived plasma cell subset; III) If the glandular micro-
environment of pSS is diseases p e c i f i ca n dt h u sd i f f e r s
from the glandular microenvironment in non-SS tissue;
IV) If GC-like structures have an impact on the type of
microenvironment seen in minor salivary glands; and
finally V) If the survival molecules contribute to the
migration of plasma cells into inflamed salivary glands.
Materials and methods
Patients and controls
Lower labial minor salivary gland biopsies from 21 con-
secutive patients fulfilling the American-European
consensus group criteria (AECC) of pSS [31] and
10 individuals not fulfilling the pSS criteria were used in
this study. All biopsies had been performed between
2004 and 2007 at the Department of Otolaryngology/
Head and Neck Surgery at Haukeland University Hospi-
tal in Bergen. All tissue sections had been previously
evaluated by an oral pathologist and the focus score
(FS) (the number of focal mononuclear cell infiltrates
with >50 mononuclear cells per 4 mm
2)w a sd e t e r -
mined. All patients had FS ≥1 and were divided in two
groups; patients with given FS equal to 1 (FS = 1) and
patients with FS equal to or more than 2 (FS ≥2).
Hematoxylin and eosin (H&E) stained formalin fixed
and paraffin embedded minor salivary gland tissue sec-
tions were further screened for the presence of germ-
inal center (GC) like structures. Individuals that were
evaluated for pSS, but did not fulfill the AECC criteria
served as non-pSS tissue controls and were divided
into chronically inflamed (CIG) (small focal infiltrates
with less than 50 cells; chronically inflamed tissue not
sufficient for SS) and normal glands (NG) (no inflam-
mation in the salivary gland tissue). Medical records
were obtained from patients’ charts at the Department
of Rheumatology, Haukeland University Hospital and
information was collected regarding routine laboratory
assessments including RF detection, antinuclear antibo-
dies (ANA), anti-Ro/SSA, anti-La/SSB, and serum
immunoglobulin levels (IgG, IgA and IgM). The char-
acteristics of patients and subjects included in the
study are shown in Table 1. The study was approved
by the Committee of Ethics at the University of Bergen
(145/96-44.96 and 242.06). All studied subjects gave
their informed consent.
Primary antibodies
The following primary anti-human antibodies were used
in this study: mouse monoclonal CD138 (1:00) (clone
MI15, Dako A/S, Glostrup, Denmark), rabbit polyclonal
IgA (1:50000) (Dako A/S), rabbit polyclonal IgG
(1:30000) (Dako A/S), mouse monoclonal Ki-67 (1:150)
(clone MIB-1, Dako A/S), rabbit monoclonal Bcl-2
(1:100) (clone E17, Abcam plc., Cambridge, UK), mouse
monoclonal CXCL12 (1:250) (clone 79014.111, R&D
Systems, Minneapolis, MN USA), rabbit polyclonal IL-6
(1:500) (Abcam plc) and rat anti-PNAd carbohydrated
epitope (clone MECA-79, BD Bioscience, Trondheim,
Norway). Isotype and concentration matched antibodies
(mouse IgG1 and rabbit Ig fraction, Dako A/S) were
used as negative controls.
Immunohistochemistry
Single-staining
Formalin fixed, paraffin embedded minor salivary glands
were cut (4 to 6 μm) on a Leica serial microtome (Leica
Instruments GmbH, Nussloch, Germany) and placed on
SuperFrost
® Plus microscope slides (Thermo Scientific,
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xylene and rehydrated through graded ethanol series
and distilled water. After heat-induced epitope retrieval
(HIER) with citrate buffer (Dako Target Retrieval Solu-
tion, pH 6.0, S1699), endogenous peroxidase activity was
blocked with 0.03% Dako Peroxidase Block for five
minutes. Sections were further incubated with primary
antibody (CD138, Bcl-2, IgA, IgG, IL-6 or PNAd) for 60
minutes, followed by incubation with horse radish per-
oxidase (HRP)-conjugated anti-mouse or anti-rabbit
EnVision+ (Dako) for 30 minutes. Except for PNAd, dia-
minobenzidine (DAB) was used as chromogen for
10 minutes in development of all antibodies. Alkaline
phosphatase (AP) and Liquid Permanent Red (LPR,
K0640, Dako, Glostrup, Denmark). were used in the
development of PNAd staining. All incubations were
performed at room temperature (RT) and Tris-buffered
saline (TBS) (pH 7.6 with 0.1% Tween) was used for 10
minutes between every step. Sections were counter-
stained with Haematoxylin (Dako S3301) for three min-
utes, dehydrated and mounted in Eukitt (O. Kindler
GmbH & Co, Freiburg, Germany).
Double-staining
Expression of Ki-67/CXCL12/IL-6 and CD138 was
detected by double-staining. Sections were pre-treated
as described above and Dako Dual Block was used for
10 minutes to block endogenous peroxidase and endo-
genous AP. The first primary antibody was incubated
for one hour at RT followed by the procedure described
in single staining. After development of the first primary
antibody with DAB, sections were washed with water
for 5 minutes, with TBS for 10 minutes and treated
Table 1 Information on patients and subjects included in the study
Patient/Subject Nr. Focus score GC+/- Age Gender Salivary secretion Ro/SSA La/SSB ANA RF IgG IgA IgM
pSS 1 1 - 48 F 2.0 - - 0.36 <16 10.0 2.3 1.3
pSS 2 1 - 50 F 1.6 nt nt nt nt nt nt nt
pSS 3 1 + 72 F 1.9 nt nt nt nt nt nt nt
pSS 4 1 - 50 F 1.1 - - 0.57 <11 10.1 1.2 0.9
pSS 5 1 - 48 F 0.2 - - 0.68 <11 10.7 0.8 0.9
pSS 6 1 + 62 F 1.7 + - 2.20 <11 13.9 1.8 3.0
pSS 7 1 - 48 F 0.7 + - 6.91 nt 19.4 4.1 0.5
pSS 8 1 - 37 F 0.5 - - 4.55 <11 15.9 3.1 1.7
pSS 9 1 - 68 F 0.8 - - 2.00 <16 9.8 2.2 0.6
pSS 10 4 - 54 F 0.1 + - 4.77 32 15.1 4.4 0.9
pSS 11 2 - 58 F 2.5 - - 0.60 nt** 12.4 1.5 1.3
pSS 12 3 + 40 F 0.2 + + nt nt nt nt nt
pSS 13 4 + 52 F 1.0 - - 0.17 nt** 12.4 2.7 1.1
pSS 14 12 + 46 F 0 - - 0.66 nt** 11.9 2.4 1.7
pSS 15 4 - 72 M 0.2 + + 6.05 nt 16.6 3.7 0.9
pSS 16 4 + 60 F 0.1 - - 8.05 <11 8.0 1.4 2.1
pSS 17 4 - 56 F 1.2 - - 0.29 <11 7.1 0.9 1.5
pSS 18 2 - 56 F 0.5 - - -* <11 9.1 0.7 1.8
pSS 19 2 - 50 F 0.8 + + 1.27 nt** nt nt nt
pSS 20 4 - 58 M 1.5 + + 9.72 <16 22.1 1.7 0.9
pSS 21 6 + 59 F 4.6 + + +* 224** 19.8 1.5 1.4
CIG 22 0 - 46 F 0.9 - - 0.39 <11 9.0 2.0 0.7
CIG 23 0 - 66 F 4.5 + - 0.77 <11 19.2 6.4 0.5
CIG 24 0 - 49 F 0.8 - - 0.1 <11 9.9 1.8 1.0
CIG 25 0 - 70 F 0.9 - - 0.39 nt nt nt nt
CIG 26 0 - 54 F 1.0 - - 0.12 <11 14.1 2.0 0.5
NG 27 0 - 54 F 0.2 - - 0.28 <11 8.8 1.1 0.4
NG 28 0 - 58 F 1.0 - - 0.45 <11 9.6 1.6 0.8
NG 29 0 - 54 F 2.1 - - 0.41 nt nt nt nt
NG 30 0 - 55 F 0 nt nt nt nt nt nt nt
CIG, chronically inflamed glands; NG, normal glands; pSS, primary Sjögren’s syndrome. Focus score: the number of focal infiltrates of more than 50 mononuclear
cells per 4 mm
2. GC+/-: presence or absence of germinal center like structures based on morphology of the infiltrates. Age, age at the time of SS diagnosis.
Gender, Female/Male. Saliva secretion, Mean un-stimulated whole saliva secretion per 15 minutes, normal values ≤1.5 ml/15 minutes. Ro-SSA and La-SSB
autoantibodies in serum, positive or negative. ANA, Antinuclear antibodies in serum: negative < 0.99, grey zone 1.00 to 1.65 and positive >1.65. * From 2009
measure as positive or negative. RF, rheumatoid factor in serum: <11 or <16 negative, 32 uncertain. ** Patients with highly positive cyclic citrullinated peptide
antibody (CCP). Immunoglobulin levels in serum, normal values: IgG 6.0 to 15.3 g/L, IgA 1.0 to 4.1 g/L and IgM 0.5 to 2.5 g/L. nt, not tested.
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primary antibody was incubated first for 60 minutes at
RT and than over night at 4°C. Binding of the second
primary antibody was detected by AP polymer and LPR
for seven minutes. Between every step sections were
washed with TBS for 10 minutes. Sections were coun-
terstained with Hematoxylin, dehydrated and mounted
in Eukitt.
Triple-staining
Expression of CD138, PNAd and CXCL12 was detected
by triple-staining. Sections were pre-treated as described
above and incubated with Dako Dual Block for 10 minutes
to block endogenous peroxidase and endogenous alka-
line phosphatase. Avidin was used for 15 minutes, TBS
for 15 minutes and Biotin for 15 minutes (Blocking Kit
Avidin/Biotin, Vector Laboratories, Burlingame, CA,
USA) to block endogenous biotin. CD138 was incubated
as the first primary antibody. The procedure for single
staining was followed. Second primary antibody PNAd
was incubated over night at 4°C, followed by 30 minutes
incubation with biotinylated rabbit -anti-rat (Dako,
E0468) antibody diluted 1:200 in 3% bovine serum albu-
min (BSA). Development of PNAd was performed by
using Vector ABC Kit for 30 minutes and LPR for
7 minutes. The third primary antibody CXCL12 was
incubated over night at 4°C followed by incubation with
Rabbit/Mouse Link (Dako, K5361) for 30 minutes. Sec-
ondary antibody, conjugated with alkaline phosphatase
labelled polymer (EnVision+ Dako, Glostrup, Denmark)
was applied for 30 minutes. Blue Vector (Vector
Laboratories, SK-5300) was used in development of
CXCL12 for four minutes. Between every step 10 min-
utes rinsing with TBS was used. Sections were counter-
stained with Dako Hematoxylin for one second and
mounted in Eukitt.
Immunofluorescence staining
Immunofluorescence was used in detection of Bcl-2
expressing plasma cells Sections were pre-treated as
described above and non-specific binding was inhibited
with TBS buffer containing 2% BSA, 10% normal serum
and 0.5% TritonX. Sections were further incubated for
one hour at RT with primary antibodies (CD138 and
Bcl-2) followed by incubation for two hours with sec-
ondary antibody; AlexaFluor488 (green) (Molecular
Probes, Invitrogen, Paisley UK) for CD138 and Alexa-
Fluor 594 (red) (Molecular Probes, Invitrogen, Paisley
UK) for Bcl-2. Between every step sections were washed
with TBS for 10 minutes. Sections were counterstained
with DAPI and mounted with Moviol.
Evaluation of staining
The minor salivary gland tissue sections were evaluated
using a light microscope (Leica DMLB, Leica Microsys-
tems Wetzlar, Wetzlar, Germany) by two investigators.
Both interstitial (small mononuclear cell clusters in
close proximity to the acinar or ductal epithelium) and
mononuclear cells in focal infiltrates were analysed.
Cells were counted using a grid and a 10× or a 40×
objective. Cells were considered positive if 50% or more
of the cell membrane, nucleus or cytoplasm were posi-
tively stained. Intensity of staining was not evaluated in
this study. For the analysis of double staining, cells were
considered in contact when more than 10% of the cell
membranes from both cells were in contact with each
other. Counted areas were randomly selected and
between three and four minor salivary glands were ana-
lysed for each patient or subject. Except for CD138
expression, the data are presented as the number of
positive cells/mm
2 of salivary gland tissue. For the
CD138 expression in the focal infiltrates the data are
presented as the percentage of CD138 positive cells of
the total number of cells.
Statistical analysis
Statistical analyses were performed using SPSS version
15.0 software (IBM, Chicago, IL, USA). Normal distribu-
tions of the results were tested by Kolmogorov-Smirnov.
All data were normally distributed and thus statistic sig-
nificance was tested by Student t-test and presented as
mean ± standard error of mean (SEM). Differences were
considered significant when P < 0.05.
Results
Study group
The pSS patients used in this study were divided into
two groups according to FS; one group consisted of
patients with FS = 1 and one group consisted of patients
with FS ≥2. By morphology, we detected GC-like struc-
tures (GC+) in salivary glands of 7/21 (33%) patients
with pSS. The majority of the GC+ patients were in the
FS ≥2 group; mean FS in the GC+ was 4.4 as compared
to 2 in the GC- patients (Table 1). Subjects not fulfilling
the criteria of pSS were also divided into two groups;
1) subjects with chronic inflammation which presented
as diffuse non-focal infiltration of cellular aggregates
with less than 50 cells in the minor salivary gland tissue
and 2) subjects with normal salivary gland histology;
occasional cellular aggregates but not more than
expected in normal tissue, and absence of focal inflam-
mation. The mean unstimulated salivary secretion levels
were lower than 1.5 ml/15 minutes in all study groups
(Table 1). Eight pSS patients were positive for Ro/SSA
or/and La/SSB. The mean antinuclear antibodies (ANA)
levels in serum were 2.47 in pSS with FS = 1, 3.56 in
pSS with FS ≥2, 0.35 in subjects with chronically
inflamed glands and 0.77 for subjects with normal gland
histology. Only one pSS patient had high amounts of
rheumatoid factor in serum; however, five pSS patients
were highly positive for cyclic citrullinated peptide
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IgG and IgA levels between the groups. The IgM levels
were significantly higher in pSS with FS ≥2 compared to
chronically inflamed (P <0 . 0 5 )a n dn o r m a l( P < 0.05)
subjects (Table 1).
High number of CD138 expressing plasma cells detected
in pSS with FS ≥2
Plasma cells in the salivary gland tissue identified by the
expression of CD138 showed both plasma blast and
mature plasma cell morphology. Cells with mature
plasma cell morphology had characteristic eccentrically
placed nucleus, prominent cytoplasm and oval shape,
whereas cells with plasma blast morphology were smal-
ler, spherical and with higher nucleus-to-cytoplasm
ratio.
CD138+ plasma cells were detected in the salivary
gland tissue of all investigated patients. In patients with
FS = 1, CD138 expressing cells were detected intersti-
tially as small cell clusters close to ductal and acinar
epithelium and in the periphery of larger infiltrates. In
the biopsy samples from patients with FS ≥2, CD138
expression was identified interstitially and both in the
periphery and within larger focal infiltrates (Figure 1A).
Further, we detected CD138+ plasma cells within
some GC-like structures as described in more detail
later.
Significantly higher numbers of CD138+ interstitial
cells were detected in pSS patients with FS ≥2 compared
to the other groups tested (Figure 1B). There were no
significant differences in the amount of CD138+ intersti-
tial cells between the pSS group with FS = 1, chronic
inflammation and normal glands (Figure 1B). When
looking at focal infiltrates, we found no significant dif-
ferences between the percentage of CD138+ cells in pSS
patients with FS = 1 and pSS patients with FS ≥2
(Figure 1C). In our material, the presence of GC-like
structures had no impact on the numbers of detected
CD138 plasma cells.
Up-regulation of IgG but not IgA expressing plasma cells
detected in pSS with FS ≥2
An analysis of immunoglobulin phenotype showed the
presence of both IgA and IgG expressing plasma cells in
the salivary gland tissue of all patients and subjects
tested (Figure 2). IgA expressing plasma cells were
detected in small cell clusters in close proximity to duc-
tal and acinar epithelium in all groups tested and in the
periphery of smaller and larger focal infiltrates in pSS
salivary glands. IgA+ cells clearly resembled plasma cell
morphology (Figure 2A). IgG expressing plasma cells
were found both inside and in the periphery of large
focal infiltrates in pSS patients with FS = 1 and FS ≥2,
whereas interstitial accumulation of IgG expressing
plasma cells was observed mostly in the pSS patients
with high FS. Similarly to IgA, IgG+ cells clearly
resembled plasma cell morphology (Figure 2B).
Approximately the same frequencies of IgA expres-
sing plasma cells were noted in the interstitial areas
of all three groups tested (Figure 2C). However, not
significantly, a reduction in IgA+ plasma cells was
noted in the focal infiltrates of pSS patients with FS ≥2
(Figure 2D).
Both pSS groups (FS = 1 and FS ≥2) and subjects with
chronically inflamed salivary glands had significantly
higher numbers of interstitial IgG plasma cells com-
pared with normal tissue. However, pSS patients with
high FS demonstrated the most prominent increase in
the interstitial IgG plasma cells (Figure 2E). The number
of IgG expressing plasma cells in the focal infiltrates was
higher in the pSS with FS ≥2 but due to great variation
within the groups, the differences were not significant
(Figure 2F).
Interestingly, the focal infiltrates of pSS patients with
FS = 1 contained similar frequencies of IgA and IgG
expressing plasma cells, whereas in the focal infiltrates
of pSS patients with high FS, the numbers of IgG
expressing plasma cells were three times higher than
numbers of IgA positive plasma cells (Figure 2D, F).
The presence of GC-like structures appeared to have no
impact on the amounts of IgA or IgG expressing plasma
cells. No correlation was detected when we compared
the increased number of IgG versus IgA plasma cells in
the salivary glands and serum IgG and IgA levels in
patients with pSS.
Accumulation of non-proliferative plasma cells in salivary
gland tissue
Since it has been proposed that the long-lived plasma
cells survive without detectable proliferation [21,32], a
Ki-67/CD138 double-staining was performed.
Ki-67 was generally expressed on mononuclear cells in
the focal infiltrates of pSS patients with both FS = 1 and
FS ≥2 and in the interstitial cells of all groups included
in this study (Figure 3). Frequencies of interstitially Ki-
67+ cells were low in the normal tissue, but increased
significantly in chronically inflamed and in pSS tissue
with FS = 1. A remarkable increase of Ki-67+ interstitial
cells was observed in the salivary glands of pSS patients
with FS ≥2 (Figure 3A). Only a slight difference was
detected in the expression of Ki-67 by focally infiltrating
cells in pSS patients with FS = 1 and in pSS patients
with FS ≥2 (Figure 3B). Moreover, GC positivity did not
seem to associate with the numbers of focally infiltrating
Ki-67+ cells.
Most of the CD138+ plasma cells did not express
Ki-67. For the pSS groups with FS = 1 and FS ≥2w e
detected on average four double-positive cells per gland.
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one double-positive cell per gland, whereas no double
positive cells were detected in normal salivary gland tis-
sue. Ki-67+ plasma cells were mainly observed in the
periphery of larger infiltrates with high proliferating
activity and in some small plasma cell aggregates often
in close proximity to vascular structures (Figure 3C).
Bcl-2 expressing plasma cells preferentially associate with
pSS high FS
In order to determine whether the accumulating plasma
cells in the minor salivary glands of pSS patients and con-
trols are primed to survive for long periods of time [33,34]
we looked at the expression of anti-apoptotic Bcl-2 protein.
Bcl-2 was expressed in the cytoplasm of mononuclear
cells both in the focal infiltrates of pSS patients and
interstitially in all study groups (Figure 4A). We
observed significantly higher expression of Bcl-2 in the
interstitial cells of pSS patients with FS ≥2c o m p a r e d
with the three other groups (Figure 4B). Furthermore,
significantly higher numbers of Bcl-2+ interstitial cells
were found in the pSS tissue with FS = 1 comparing
with normal, but not with chronically inflamed tissue
(Figure 4B). When evaluating focal infiltrates, a dramatic
increase in the levels of Bcl-2 expressing cells was
observed in the pSS with high FS comparing with pSS
with FS = 1 (Figure 4C). GC positivity did not seem to
influence the numbers of Bcl-2 positive cells in the sali-
vary gland tissue included in this study.
Notably, no Bcl-2 negative plasma cells could be
detected in the salivary glands of pSS patients (both
FS = 1 and FS ≥2) (Figure 5A-D). In the chronically
inflamed and normal tissue both Bcl-2+ and Bcl-2-
plasma cells were observed (Figure 5E-H)). Even though
it is difficult to evaluate the intensity of the Bcl-2
expression, a more distinct cytoplasmic Bcl-2 staining
was noted in plasma cells from pSS salivary glands com-
pared to plasma cells from subjects with chronic inflam-
mation and normal salivary gland tissue (Figure 5).
Plasma cells in pSS salivary glands located in close
contact with CXCL12 expressing cells
CXCL12 (also known as stromal derived factor 1; SDF-1)
plays a crucial role in the migration and survival of
plasma cells [22,23,27]. To investigate the possibility of
CXCL12 to facilitate plasma cell survival in the inflamed
salivary gland tissue, a double-staining with anti-CXCL12
and anti-CD138 was performed.
CXCL12 staining was detected on acinar and ductal
epithelial cells in pSS patients and to a lesser extent in
chronic inflammation and normal subjects (Figure 6A).
CXCL12 was also expressed on the mononuclear cells
interstitially in pSS and chronic inflammation subjects
Figure 1 CD138 expressing plasma cells in salivary glands of
pSS patients and non-SS controls. A) CD138+ plasma cells
(brown) in pSS patient with FS = 1, a pSS patient with FS = 4, in a
subject with chronically inflamed glands (CIG) and a subject with
normal gland (NG) histology. CD138+ plasma cells were detected
interstitially as small cell clusters close to ductal and acinar
epithelium in all patients and controls. In pSS glands with FS = 1,
plasma cells were detected mainly in the periphery of the infiltrates,
whereas in pSS glands with high FS, plasma cells were detected
both in periphery and within the infiltrates. B) CD138+ cells
presented as number of interstitial plasma cell per mm
2 or as
C) percentage of CD138 positive plasma cells in the focal infiltrates.
Grey bars represent FS = 1 (n = 6), black bars represent FS ≥2( n =
10), striped bars represent chronic inflammation (n = 5) and white
bars represent normal gland histology (n = 5). Results presented as
mean ± SEM. Statistical analyses determined by Kolmogorov-
Smirnov and Student t-test (*P < 0.05, **P < 0.005).
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of CXCL12 was detected on the interstitial cells in nor-
mal salivary gland tissue (Figure 6A). Additionally, we
observed expression of CXCL12 by resident adipocytes
p r e s e n ti ns o m ea r e a so fs a l i v a r yg l a n dt i s s u eo fp S S
patients (Figure 6B).
In pSS patients and chronic inflammation subjects,
CD138+ interstitial plasma cells were mainly observed
in close proximity to the CXCL12 expressing ductal and
acinar epithelium and CXCL12 expressing mononuclear
cells (Figure 6A). In contrast, in normal tissue clusters
of CD138+ plasma cells were mainly observed in close
Figure 2 IgA and IgG expressing plasma cells in salivary glands of pSS patients and non-SS controls. A) IgA and B) IgG positive plasma
cells detected in salivary glands of a pSS patient with FS = 1, a pSS patient with FS = 4, in a subject with chronically inflamed glands (CIG) and
a subject with normal gland (NG) histology. Inserts represent higher magnifications of IgA or IgG plasma cells for each group. IgA expressing
plasma cells were detected interstitially as small cell clusters close to ductal and acinar epithelium in all groups tested and in the periphery of
infiltrates in pSS with FS = 1 and FS ≥2 (A). IgG expressing plasma cells were found both inside and in the periphery of large focal infiltrates in
pSS patients with FS = 1 and FS ≥2, whereas interstitial accumulation of IgG expressing plasma cells was observed mostly in the pSS patients
with high FS (B). C) Amount of IgA or E) IgG positive interstitial plasma cells presented as number of cells/mm
2 and D) IgA or F) IgG positive
cells in the focal infiltrates presented as number of positive cells per mm
2. Grey bars represent FS = 1 (n = 8), black bars represent FS ≥2( n = 7),
striped bars represent chronic inflammation (n = 5) and white bars represent normal gland histology (n = 5). Results presented as mean ± SEM.
Statistical analyses determined by Kolmogorov-Smirnov and Student t test (*P < 0.05).
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Page 7 of 18Figure 3 Proliferating and non-proliferating plasma cells in salivary glands of pSS patients and non-SS controls. A) Amount of Ki-67+
interstitial cells and B) Ki-67+ cells in the focal infiltrates presented as number of cells per mm
2. Grey bars represent FS = 1 (n = 8), black bars
represents FS ≥2( n = 7), striped bars represent chronic inflammation (n = 5) and white bars represent normal gland histology (n = 5). Results
presented as mean ± SEM. Statistical analyses determined by Kolmogorov-Smirnov and Student t test (*P < 0.05, **P < 0.005 and ***P 0.001).
C) Double-staining with CD138 plasma cell marker (red) and Ki-67 proliferation marker (brown) in a pSS patient with FS = 1, in a pSS patient
with FS = 4, in a subject with chronically inflamed glands (CIG) and a subject with normal gland (NG) histology. Inserts represent higher
magnifications of CD138+ Ki-67+ plasma cells. Ki-67+ plasma cells were mainly observed in the periphery of larger infiltrates with high
proliferating activity and in some small plasma cell aggregates often in close proximity to vascular structures.
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Page 8 of 18Figure 4 Bcl-2 expression in infiltrating lymphocytes of pSS patients and non-SS controls. A) Bcl-2 detected in salivary glands of a pSS
patient with FS = 1, a pSS patient with FS = 4, in a subject with chronically inflamed glands (CIG) and a subject with normal gland (NG)
histology. Bcl-2 was expressed in the cytoplasm of mononuclear cells both in the focal infiltrates of pSS patients and interstitially in all study
groups. B) Amount of Bcl-2+ interstitial cells and C) Bcl-2+ cells in the focal infiltrates presented as number of cells per mm
2. Grey bars represent
FS = 1 (n = 8), black bars represent FS ≥2( n = 7), striped bars represent chronic inflammation (n = 5) and white bars represent normal gland
histology (n = 5). Results presented as mean ± SEM. Statistical analyses determined by Kolmogorov-Smirnov and Student t test (*P < 0.05,
**P < 0.005 and ***P < 0.001).
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Page 9 of 18Figure 5 Bcl-2 expression in infiltrating plasma cells of pSS patients and non-SS controls. A) CD138 (green) and Bcl-2 expressing cells
(red) detected in a pSS patient with FS = 1. DAPI (blue) was used for nuclear staining of salivary glands cells. Merge image shows double
positive (CD138 and Bcl-2) cells. B) Higher magnifications of CD138 (green) and Bcl-2 (red) expressing cells in a pSS patient with FS = 1. Merge
image with CD138+ Bcl-2+ plasma cells. Only Bcl-2+ plasma cells were detected in the salivary glands of pSS patients with FS = 1. C) CD138
(green) and Bcl-2 expressing cells (red) detected in a pSS patient with FS = 4. DAPI (blue) was used for nuclear staining of salivary glands cells.
D) Higher magnifications of CD138 (green) and Bcl-2 (red) expressing cells in a pSS patient with FS = 4. Merge image with CD138+ Bcl-2+
plasma cell. Only Bcl-2+ plasma cells were detected in the salivary glands of pSS patients with FS ≥2. E) CD138 (green) and Bcl-2 expressing cells
(red) detected in a subject with chronically inflamed glands (CIG). DAPI (blue) was used for nuclear staining of salivary glands cells. F) Higher
magnifications of CD138 (green) and Bcl-2 (red) expressing cells in a subject with CIG. Merge image with CD138+ Bcl-2+ and CD138+ Bcl-2-
plasma cells. Both Bcl-2+ and Bcl-2- plasma cells were detected in the chronically inflamed tissue. G) CD138 (green) and Bcl-2 expressing cells
(red) detected in a subject with normal gland (NG) histology. DAPI (blue) was used for nuclear staining of salivary glands cells. H) Higher
magnifications of CD138 (green) and Bcl-2 (red) expressing cells in a subject with NG histology. Merge image with CD138+ Bcl-2+ and CD138+
Bcl-2- plasma cells. Both Bcl-2+ and Bcl-2- plasma cells were detected in the normal tissue.
Szyszko et al. Arthritis Research & Therapy 2011, 13:R2
http://arthritis-research.com/content/13/1/R2
Page 10 of 18Figure 6 Double staining of CXCL12 and CD138 in salivary glands of pSS patients and non-SS controls. A) Double-staining with CD138
plasma cell marker (brown and CXCL12 (red) in a pSS patient with FS = 1, a pSS patient with FS = 4, in a subject with chronic inflammation and a
subject with normal gland histology. Inserts represent higher magnifications of CD138+ plasma cells (brown) in contact with CXCL12 expressing
cells (red). CXCL12 was detected on acinar and ductal epithelium in all three groups tested and on the mononuclear cells in pSS and chronically
inflamed but not normal salivary glands. Plasma cells were in contact with both CXCL12 expressing epithelium and CXCL12 expressing cells.
B) Expression of CXCL12 (blue) on adipocytes in a pSS patient with FS = 4. Plasma cells were in close contact with CXCL12 expressing adipocytes in
pSS glands with high FS. C) Amount of CD138+ interstitial plasma cells in contact with CXCL12+ cells and D) Amount of CD138 positive cells in
contact with CXCL12 positive cells in the focal infiltrates presented as number of cells per mm
2. Grey bars represent FS = 1 (n = 6), black bars
represent FS ≥2( n = 8), striped bars represent chronic inflammation (n = 5) and white bars represent normal gland histology (n =5 ) .R e s u l t s
presented as mean ± SEM. Statistical analyses determined by Kolmogorov-Smirnov and Student t-test (*P < 0.05 and ***P <0 . 0 0 1 ) .
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Page 11 of 18proximity to CXCL12 negative acini. Interestingly, small
aggregates of CD138+ plasma cells were in close contact
to CXCL12 expressing adipocytes in pSS salivary gland
tissue.
Significantly higher numbers of CD138+ interstitial
plasma cells were in contact with CXCL12 expressing
cells in pSS patients with FS ≥2 compared to chronic
inflammation and normal subjects (Figure 6C).
However, there were no statistical differences in the
numbers of interstitial plasma cells in contact with
CXCL12 between pSS with FS = 1 and chronic
inflamed tissue. In normal glands, only few plasma
cells were in contact with CXCL12 expressing epithe-
lium (Figure 6C).
Plasma cells residing in the focal infiltrates of pSS
patients were in contact with CXCL12 expressing cells
(Figure 6A). The frequency of interactions between the
CD138+ plasma cells and CXCL12 were significantly
increased in the focal infiltrates of pSS with FS ≥2c o m -
pared with interactions seen in the pSS tissue with FS =
1 (Figure 6D).
Plasma cells in pSS salivary glands accumulate
in IL-6 rich niches
IL-6 cytokine has proven to be vital for plasma cell
s u r v i v a l[ 2 2 ] .T h u s ,w ep e r f o rmed a double-staining for
IL-6 and CD138, to investigate if IL-6 can support the
survival of plasma cells in the salivary gland tissue.
IL-6 was expressed primarily on the salivary gland
interstitial cells in all groups studied and the majority of
salivary gland epithelial cells were negative for this cyto-
kine (Figure 7). Only scattered IL-6+ acinar epithelial
cells were detected in some of the pSS patients (data
not shown). IL-6 was demonstrated within the majority
of the focal infiltrates; however, the number of cells
expressing IL-6 was generally higher in the pSS patients
with FS ≥2 (Figure 7A).
Salivary glands from pSS patients had significantly
higher numbers of CD138+ plasma cells in close contact
with IL-6 producing cells than plasma cells in chronically
inflamed and normal tissue (Figure 7B). Moreover, the
number of plasma cells that interacted with IL-6, increased
drastically from pSS patients with FS = 1 to pSS with FS
≥2 (Figure 7B). Since only few IL-6 expressing cells were
detected in chronically inflamed and normal subjects, the
contact between these cells and CD138+ plasma cells was
rare (Figure 7B).
When investigating focal infiltrates, we detected higher
numbers of CD138+ plasma cells in close proximity to
the IL-6 producing cells in the pSS with high FS com-
pared with pSS with FS = 1. However, due to variation
in the presence of IL-6 producing cells, these differences
were not significant (Figure 7C).
High endothelial venules retain strongly IL-6 and more
moderately CXCL12 in pSS salivary glands
Formation of specific blood vessels called high
endothelial venules (HEVs) has been detected in the
inflamed tissue of autoimmune diseases such as
the synovium in rheumatoid arthritis and in salivary
gland tissue of SS patients [35-37]. However, little is
known about the phenotype and the function of these
structures at the site of inflammation. To further char-
acterize the distribution pattern of HEVs in the salivary
glands of pSS and in particular their possible contribu-
tion to ‘survival niches’ for plasma cells, we performed
for the first time a IHC triple staining with PNAd,
CXCL12 and CD138. In addition, consecutive salivary
gland tissue sections were single stained with PNAd
and IL-6.
HEVs were detected interstitially in all groups tested.
In pSS patients, HEVs were often localized in close
proximity to and within focal infiltrates. Occurrence of
HEVs increased with increasing inflammation and thus
high numbers were detected in pSS patients with FS ≥2
(Figure 8A, B). Using the triple staining, only few of the
HEV endothelial cells in pSS salivary glands were
expressing CXCL12. CD138+ plasma cells were often
observed in an extravascular location, sometimes tightly
adherent to both CXCL12 positive and CXCL12 nega-
tive HEVs (Figure 8C, D). No CXCL12 positive HEVs
were recognized in chronically inflamed or in normal
salivary gland tissue.
To gain further insight into the mode of chemokine
binding to HEVs, we next investigated the possible rela-
tionship between IL-6 and HEVs in the salivary glands.
Indeed most of HEVs in our selected pSS material
expressed IL-6 (Figure 9).
Discussion
The present study demonstrates that minor salivary
glands of pSS patients provide niches rich in specific fac-
tors vital for survival of plasma cells. Notably, salivary
glands from pSS patients with severe inflammation (high
FS) expressed significantly more of these factors than the
three other groups tested. To our knowledge, we are the
first to demonstrate by using double and triple immuno-
histochemistry, that CD138+ plasma cells are located in
close proximity to ductal and acinar epithelium as well as
to mononuclear cells within the focal infiltrate expressing
survival factors CXCL12 and IL-6. An association
between the accumulation of plasma cells and CXCL12
expressing HEVs were also detected exclusively in pSS
salivary gland tissue. Furthermore, plasma cells accumu-
lating in the salivary glands of pSS were found to be
non-proliferating, Bcl-2 expressing cells and could possi-
bly be the long-lived plasma cell subset.
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Page 12 of 18When investigating the presence of plasma cells, we
detected significantly higher numbers of these cells in the
salivary gland tissue of pSS patients with FS ≥2c o m p a r e d
to the three other groups. Interestingly, the numbers of
plasma cells in FS = 1 group did not differ from chroni-
cally inflamed and normal group. The regulation of
plasma cell differentiation and accumulation in the
inflamed salivary gland tissue is complex and not defined.
The significant increase in plasma cells in the salivary
glands with high FS could be due to increased migration
into the tissue and/or a consequence of B-cell activation
and differentiation in the ectopic germinal centres that
can be formed in the salivary glands of SS patients
[9,17,38,39]. In correlation with previous studies [17], the
presence of GC-like structures was detected mostly in
pSS patients with more severe inflammation (high FS).
No association was noted between the number of plasma
cells and presence of GC-like structures in our patients.
However, based on the limited GC+ patients included in
this study only a trend could be indicated. Another possi-
bility could be that plasma cells are produced in the tis-
sue without involvement of GC-like structures as it has
been shown that class-switch recombination and somatic
hypermutation of B-cells can also occur outside of GC
[40]. In any case, whether migrated or not, the presence
of high numbers of CD138+ plasma cells implies that the
microenvironment of the salivary glands with high FS
provide factors/signals necessary for the maintenance and
survival of these cells.
There has been some interest in the IgG versus IgA
plasma cell expression in the salivary glands of SS
patients especially between the primary and secondary
SS. In agreement with previous IHC study on SS salivary
gland tissue [41], examination of immunoglobulin phe-
notype of plasma cells in our study, revealed signifi-
cantly higher numbers of interstitial IgG plasma cells in
pSS patients compared with non-SS control. Addition-
ally, our study reveals that when divided in groups, pSS
patients with FS ≥2 had significantly more interstitial
IgG plasma cells but not focally infiltrating cells than
pSS patients with FS = 1. Hence, we show that the
increase in IgG plasma cells is associated with more
severe inflammation in the salivary gland tissue of pSS
patients.
Figure 7 Double staining of IL-6 and CD138 in salivary glands of pSS patients and non-SS controls. A) IL-6 expression (brown) and
CD138+ plasma cells (red) detected in a pSS patient with FS = 1, a pSS patient with FS = 4, in a subject with chronic inflammation and a
subject with normal gland histology. IL-6 was expressed on the interstitial cells in all groups studied and the majority of salivary gland epithelial
cells were negative for IL-6. In the focal infiltrates IL-6 expressing cells were mostly detected in pSS patients with FS ≥2. Interaction between
CD138+ plasma cells and IL-6 expressing cells were detected in the pSS glands with both FS = 1 and FS ≥2 and not in chronically inflamed or
normal glands. Interactions between IL-6 and CD138 plasma cells are indicated by arrows. B) Amount of CD138+ interstitial cells in contact with
IL-6+ cells and C) amount of CD138+ plasma cells in contact with IL-6+ cells in the focal infiltrates presented as number of cells per mm
2. Grey
bars represent FS = 1 (n = 9), black bars represent FS ≥2( n = 8), striped bars represent chronic inflammation (n = 5) and white bars represent
normal gland histology (n = 5). Results presented as mean ± SEM. Statistical analyses determined by Kolmogorov-Smirnov and Student t-test
(*P < 0.05, **P < 0.005 and ***P < 0.001).
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Page 13 of 18In contrast to a previous report [41], we detected
similar IgA profiles in all three groups tested. Thus, it
seems that the IgG plasma cells are the ones responsible
for the increase of the CD138+ plasma cells that we
observed in the salivary glands with high FS. However,
further studies by use of double staining are needed to
confirm this hypothesis. These findings are consistent
with our previous studies [42] in which a similar predo-
minance of IgG versus IgA autoantibody production by
single cells dispersed from SS salivary glands was
detected by use of the ELISPOT essay.
Based on studies of murine bone marrow and splenic
plasma cells, it has been speculated whether non-
proliferating plasma cells are cells that are able to sur-
vive for long period of times [21,32]. In this context, we
examined the proliferation and survival capacity of sali-
vary gland plasma cells by using double staining immu-
nohistochemistry (IHC) with CD138/Ki-67 and CD138/
Bcl-2. Interestingly, as detected by the lack of Ki-67,
plasma cells present in the salivary glands of all three
groups tested were non proliferating cells.
In addition, all CD138 plasma cells present in salivary
glands of pSS patients expressed high levels of anti-
apoptotic Bcl-2 protein, whereas both Bcl-2+ and Bcl-2-
plasma cells were present in the chronically inflamed
and normal tissue. This points to the fact that plasma
Figure 8 Triple staining of CXCL12, PNAd and CD138 in salivary glands of pSS patients and non-SS controls. A) Amounts of PNAd+ HEVs
in the interstitium and B) in the focal infiltrates in salivary glands presented as number of cells per mm
2. Grey bars represent FS = 1 (n =9 ) ,b l a c k
bars represent FS ≥2( n = 10), striped bars represent chronic inflammation (n = 5) and white bars represent normal gland histology (n = 5). Results
presented as mean ± SEM. Statistical analyses determined by Kolmogorov-Smirnov and Student t-test (*P <0 . 0 5 ,* * P < 0.005 and ***P <0 . 0 0 1 ) .
C) CXCL12 expression (blue), PNAd expression (red) and CD138+ plasma cells (brown) detected in a pSS patient with FS = 1, a pSS patient with FS
= 4, in a subject with chronic inflammation and a subject with normal gland histology. PNAd +HEVs were mainly detected in the close proximity or
inside of the infiltrates in the pSS glands. CD138+ plasma cells were observed tightly adherent to both CXCL12 positive and CXCL12 negative HEVs.
However, only few HEVs expressed CXCL12. D) Higher magnification of CXCL12 expression (blue) detected in some of the PNAd+ HEVs (red).
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Page 14 of 18cells marked for survival are unregulated in the salivary
glands of pSS patients compared to non-SS salivary
gland tissue.
Bcl-2 is a protein that regulates survival of lympho-
cytes in a mitochondria-dependent way and has pre-
viously been detected in plasma cells isolated from
blood, bone marrow and to some extent in plasma cells
from tonsils [33,34]. Its importance in regulation of
anti-apoptotic processes in the plasma cell population
has been extensively demonstrated in multiple myeloma
cells [43-45]. In accordance, the potential of IL-6 to
induce Bcl-2 expression has been demonstrated [46].
Whether IL-6 survival factor identified in this study
induce the Bcl-2 expression detected in pSS salivary
gland plasma cells, remains to be elucidated.
There is increasing evidence suggesting that the life
time of plasma cells is determined by the environment
rather than intrinsic factors [33]. Bone marrow studies
have revealed that a proper plasma cell survival environ-
ment comprises chemokines and cytokines such as
CXCL12 and IL-6 [22,23,27-29]. Based on these obser-
vations, we characterized in detail the expression pattern
of CXCL12 and IL-6 in the salivary glands of pSS
patients, chronically inflamed and normal salivary gland
tissue.
We detected CXCL12 on acinar and ductal epithelium
in all study groups; however the most prominent expres-
sion of this chemokine was detected in pSS patients
with FS ≥2. In addition, we detected CXCL12 expressing
cells in the focal infiltrates, with a significant increase in
CXCL12 expression levels in the pSS salivary glands
w i t hh i g hF S .E x p r e s s i o no fC X C L 1 2i ns a l i v a r yg l a n d s
of SS patients have been reported earlier by us and
others [12,17,47]. In this study we have extended these
results by showing that when dividing pSS patients
according to severity of inflammation, different CXCL12
expression pattern appeared.
To our knowledge, we are the first to show that
CD138+ plasma cells present in pSS and chronically
inflamed salivary glands clearly interact with CXCL12
expressing ductal epithelium and acini and with
CXCL12 expressing cells detected in the focal infiltrates.
These interactions were by far most abundant in the
pSS patients with high FS. CXCL12 has been shown to
be vital in the migration and survival of plasma cells
[20,48-50] and thus it is possible that also in the
inflamed salivary glands these processes are directed by
expression of CXCL12.
It is important to keep in mind that in addition to the
infiltration of mononuclear cells there is also atrophy,
accumulation of adipose tissue and fibrosis in some of
the salivary glands from pSS patients. Only a few studies
have concerned the role of adipocytes in SS-lesions.
Recently, the expression and possible immunoregulatory
functions of adipocyte-derived adiponectin have been
reported [51,52]. In our study, we describe for the first
time that resident adipocytes in the salivary gland tissue
of SS patients express CXCL12. This is in accordance
with the recognition of adipose tissue as a new player in
immune reactions [53]. Indeed, further investigation is
needed in order to elucidate interactions between the
adipocytes and other elements of the specific milieu of
SS [53].
To further examine possiblep l a s m ac e l ls u r v i v a l
niches, we studied the expression of IL-6 cytokine. We
observed that the expression of IL-6 was highly up-
regulated in the salivary glands of pSS patients and
increased significantly with increasing FS. Interestingly,
t h e r ew e r eo n l yaf e wI L - 6e x p r e s s i n gc e l l si nt h e
chronically inflamed tissue and almost no IL-6 expres-
sion was detected in glands with normal histology. IL-6
is an inflammatory cytokine that induces anti-apoptotic
Figure 9 Serial staining of IL-6 and PNAd in salivary glands of
a pSS patient. IL-6 and PNAd stainings of pSS glands were
performed as serial immunohistochemistry to detect possible
colocalisation. The same structures in the two sections are marked
as * and **. Colocalisations of IL-6 and PNAd are marked with
numbers from 1 to 7. Most of HEVs expressed IL-6.
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Page 15 of 18signals in plasma cells [22]. It is produced by bone mar-
row stromal cells and is an important factor of bone
marrow survival niches. We observed that plasma cells
accumulating in the salivary glands of pSS patients
interact and are in close proximity to the IL-6 produ-
cing cells.
HEVs facilitate migration of lymphocytes into the
lymph nodes and Payer’s patches by binding certain che-
mokines such as CCL19, CCL21, CXCL12 and CXCL13
(reviewed in [54]). Interestingly, formation of HEVs has
been detected in the inflamed tissue of different autoim-
mune diseases such as rheumatoid arthritis and SS
[35-37]. However, little is known about the properties
and contribution of these specialized vascular structures
in the migration and retention of cells in the lymphoid
compartment of salivary gland tissue of SS patients.
Therefore, by using antibodies against PNAd epitope,
we first investigated the expression pattern of HEVs in
the salivary glands of pSS patients compared to controls.
We detected high numbers of HEVs in pSS patients by
comparing with chronically inflamed and normal tissue.
In contrast to lymph node HEVs [55], only a few sali-
vary gland HEVs were binding CXCL12. In contrast,
CXCL12 chemokines were prominently detected in
PNAd negative blood vessels. These results indicate that
ectopic HEVs present in the salivary glands of pSS
patients have different chemokine expression pattern
than HEVs present in secondary lymphoid tissues.
Given the demonstrated upregulation of IL-6 expression
and selective accumulation of plasma cells in IL-6 rich
areas in our analysis, we next investigated whether sali-
vary gland HEVs could bind this factor. A frequent colo-
calisation between IL-6 and HEVs were detected in the
salivary glands of pSS. This finding highlights the poten-
tial of HEVs not only to regulate the navigation of lym-
phoid cells but also their ability to retain important
survival factors for plasma cells. Further investigation
will shed light into the biological significance of these
findings.
Conclusions
In this initial study, specific factors were identified sup-
porting the presence of plasma cell survival niches in
the salivary glands of pSS patients. Survival potential of
plasma cells and presence of survival niches increased
with severity of the pSS disease (high FS). Our results
suggest that plasma cells accumulating in the salivary
glands of pSS patients are located in niches rich in
CXCL12 and IL-6. Our data do not exclude the exis-
tence of other factors important for plasma cell survival
in the salivary gland environment. The importance of
the complex milieu of pSS salivary glands should be
further studied in more detail as our understanding of
the local factors necessary for plasma cell survival at the
site of inflammation could result in discovery of more
selective therapeutic options.
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